List of Excipients in Branded Drug ZINECARD

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia and Upjohn Company LLC	ZINECARD	dexrazoxane	0013-8717	HYDROCHLORIC ACID

Zinecard Excipient Strategy and Commercial Opportunities for Dexrazoxane Injection

Last updated: August 21, 2026

Zinecard is a sterile, lyophilized dexrazoxane hydrochloride injection used to reduce anthracycline-associated cardiotoxicity in selected patients receiving doxorubicin. Its excipient platform is deliberately minimal: mannitol is the principal listed inactive ingredient, while sterile water for injection and compatible infusion fluids are used during reconstitution and administration. The strongest commercial opportunities are therefore not based on complex excipient composition patents. They are based on supply reliability, vial efficiency, reconstitution simplification, stability, hospital workflow, and differentiated injectable presentations.

What is Zinecard and how is it regulated?

Zinecard contains dexrazoxane hydrochloride, the hydrochloride salt of dexrazoxane. The product is administered intravenously before doxorubicin in patients who require continued doxorubicin treatment after reaching a cumulative exposure associated with increased cardiomyopathy risk.[1]

What is the FDA-approved use of Zinecard?

The U.S. label identifies Zinecard for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and require continued doxorubicin therapy.[1]

Dexrazoxane is also marketed under the Totect brand for anthracycline extravasation. Totect and Zinecard are related products but have different labeled indications, dosing instructions, and commercial positioning. A formulation strategy for Zinecard cannot assume automatic interchangeability with Totect.

What is the FDA regulatory status of Zinecard?

Zinecard was approved under NDA 020212. The product is a prescription sterile injectable and is subject to the technical requirements applicable to parenteral drug products, including sterility assurance, particulate control, container-closure integrity, endotoxin control, assay, impurities, reconstitution performance, and stability.[1,2]

The narrow labeled population limits the size of the branded market. Demand is linked to anthracycline use, oncology treatment protocols, and institutional cardioprotection practices rather than broad outpatient prescribing.

What excipients are used in Zinecard?

Zinecard uses a low-excipient lyophilized formulation. The U.S. prescribing information identifies mannitol as the inactive ingredient.[1]

Component	Role in the product	Commercial significance
Dexrazoxane hydrochloride	Active pharmaceutical ingredient	Determines potency, impurity profile, and dose-volume requirements
Mannitol	Bulking agent and lyophilization aid	Supports cake structure, fill uniformity, and reconstitution
Sterile Water for Injection	Reconstitution vehicle	Required for preparation before further dilution
Compatible infusion solution	Administration vehicle after reconstitution	Affects in-use stability and pharmacy workflow

The formulation does not depend on a complex surfactant, preservative, oil, or polymer system. That reduces excipient-related safety and compatibility risks but also limits the scope for composition-based differentiation.

Why is mannitol important in the Zinecard formulation?

Mannitol is widely used in sterile lyophilized products because it can provide a stable and visually acceptable freeze-dried cake. It also increases solid content, which supports vial handling and dose uniformity.

Mannitol is not a proprietary barrier. Multiple suppliers can generally qualify pharmaceutical-grade material, subject to specifications, elemental impurities, bioburden, endotoxin, particle profile, and change-control requirements. The commercial value comes from manufacturing control and validated performance rather than exclusivity in the excipient itself.

Does Zinecard contain preservatives?

The product is a single-dose sterile injectable and is not positioned as a multidose preserved formulation. Avoiding preservatives is appropriate for oncology intravenous use, where preservative exposure and compatibility can create additional clinical and regulatory burdens.[1]

Does Zinecard contain sodium chloride or a surfactant?

The listed inactive ingredient in the vial is mannitol. Sodium chloride, surfactants, and other excipients should not be assumed to be part of the lyophilized product unless identified in the approved labeling or a regulatory filing. The clinical preparation may involve a separate infusion solution, but that does not make the infusion vehicle an excipient in the marketed vial.

What formulation patents protect Zinecard?

The principal intellectual-property value in a Zinecard-like product is unlikely to come from the basic mannitol-containing formulation. Mannitol is a conventional pharmaceutical excipient, and the dosage form is a conventional sterile lyophilized powder for injection.

Are there active composition patents on Zinecard?

The approved product’s commercial protection should be analyzed through current FDA Orange Book records, issued patents, patent-term adjustments, regulatory exclusivity, and any listed method-of-use claims. The FDA label itself does not establish a broad, active formulation-patent barrier for mannitol-based dexrazoxane injection.[1,3]

A generic applicant would typically examine:

• Dexrazoxane hydrochloride composition claims.
• Lyophilized injectable formulation claims.
• Reconstitution and dilution claims.
• Stability claims.
• Manufacturing and impurity-control claims.
• Method-of-use claims for anthracycline cardioprotection.
• Any patents listed against NDA 020212 in the current Orange Book.

The existence of historical patents does not establish current enforceability. Patent term, terminal disclaimers, maintenance fees, prosecution history, and claim scope control the practical risk.

What method-of-use patents could affect generic entry?

Potential method-of-use claims could cover administering dexrazoxane before doxorubicin, using a specific dexrazoxane-to-doxorubicin dose ratio, or treating patients above a cumulative anthracycline exposure threshold.

These claims may be commercially relevant even where the formulation itself is unprotected. A generic applicant could use a section viii statement to omit patented indications from labeling where permitted, while marketing for nonprotected uses. The feasibility depends on the exact Orange Book listing, claim language, labeling, and the scope of the proposed generic label.[3,4]

When does Zinecard lose exclusivity?

Zinecard’s original market protection is mature. The product was approved in the 1990s, and its regulatory exclusivity period has expired. The current competitive question is therefore generic availability, patent listing status, and the ability of manufacturers to maintain reliable sterile injectable supply.

What is the Orange Book status of Zinecard?

The Orange Book is the controlling source for current listed patents, therapeutic-equivalence ratings, and approved reference-product information.[3] Zinecard should be evaluated by NDA 020212 and the relevant dexrazoxane injection entries, rather than by brand name alone.

A practical diligence review should separate:

Issue	Why it matters
Reference listed drug status	Determines the ANDA reference product
Listed patents	Determines Paragraph IV or section viii strategy
Exclusivity codes	Determines whether an ANDA can be approved
Therapeutic-equivalence rating	Supports substitution and formulary access
Strength and dosage form	Prevents comparison against unrelated dexrazoxane products
Label restrictions	Determines whether a generic can use the full indication

Which companies are challenging Zinecard with generic products?

The relevant competitive set includes manufacturers of dexrazoxane hydrochloride for injection and suppliers of hospital oncology injectables. Company participation can change as ANDAs are approved, withdrawn, transferred, or placed on shortage-related allocation.

A commercial diligence process should distinguish between:

1. Approved ANDA holders.
2. Contract manufacturers supplying an ANDA holder.
3. Authorized distributors.
4. Manufacturers supplying dexrazoxane for a different indication or brand.
5. Products listed as therapeutically equivalent in the Orange Book.

Generic competition is often less predictable in small oncology injectables than in large oral-solid markets. A nominally approved competitor may have limited commercial distribution, intermittent supply, or no active institutional contracting position.

What Paragraph IV challenges and litigation affect Zinecard?

Paragraph IV risk depends on active Orange Book-listed patents. Because Zinecard is an established product, the highest-probability pathway for a generic entrant is an ANDA with a Paragraph III certification, a section viii statement, or a Paragraph IV certification directed to any remaining listed patent.

The litigation risk is usually lower when:

• The relevant formulation patents have expired.
• The reference product has a simple excipient profile.
• The generic can match the labeled concentration and reconstitution procedure.
• Any method-of-use patents can be carved out.
• No patent covers a clinically necessary administration step.

Potential litigation could still arise from formulation, stability, manufacturing, or use claims. A patent search should cover Pfizer and predecessor assignees, dexrazoxane, dexrazoxane hydrochloride, lyophilized injections, anthracycline cardioprotection, and the NDA’s Orange Book entries.

No broad settlement agreement should be inferred from the absence of public litigation involving a specific applicant. ANDA litigation, licensing arrangements, and commercial supply agreements may not disclose the full economics of the market.

What formulation improvements create commercial opportunities?

The best opportunities are incremental and operational.

Ready-to-use or reduced-reconstitution presentations

Zinecard preparation requires pharmacy handling before administration. A ready-to-use liquid, dual-chamber vial, or simplified reconstitution system could reduce preparation time and manipulation risk. The principal development barriers would be chemical stability, container compatibility, extractables and leachables, particulate control, and shelf-life.

A ready-to-use product would need a clear economic benefit because hospitals may prefer the lower cost of a conventional lyophilized generic.

Improved vial sizes and dose efficiency

Zinecard is supplied in 250 mg and 500 mg vial strengths.[1] A manufacturer could evaluate:

• A higher-strength vial for large adult doses.
• A smaller vial for weight-based or lower-dose use.
• Packaging that reduces partial-vial waste.
• Dual-strength cartons designed around common oncology dosing.
• Dose-banding support for institutional protocols.

Dose efficiency is commercially important because dexrazoxane is administered according to the doxorubicin dose. A vial configuration that reduces discarded product can improve the hospital’s total acquisition-cost calculation even if the unit price is higher.

Closed-system transfer and pharmacy workflow

A proprietary transfer device, reconstitution adapter, or integrated vial system could reduce compounding steps. The device would require separate design-control, human-factors, compatibility, and regulatory analysis. Its strongest value proposition would be workflow standardization rather than new pharmacology.

Stability and transport improvements

A formulation with longer permissible in-use stability or greater resistance to temperature excursions could help hospitals, oncology pharmacies, and distributors. The commercial opportunity depends on proving a meaningful extension without adding an unstable surfactant or complex buffer system.

Pediatric and specialty-oncology positioning

The U.S. Zinecard label is narrow, while dexrazoxane use has developed across pediatric and adult oncology settings. A sponsor could pursue evidence and labeling strategies for populations in which anthracycline cardioprotection is clinically relevant, subject to FDA requirements and the applicable benefit-risk record.

A new indication may create regulatory value even when the core formulation is generic. It also creates method-of-use patent opportunities if the clinical regimen, patient population, biomarker, or dosing schedule is sufficiently novel and patentable.

How strong is the Zinecard patent estate?

The patent estate is likely moderate to weak as a barrier to a conventional dexrazoxane lyophilized generic, but stronger around differentiated delivery, new indications, and manufacturing controls.

Patent category	Likely barrier strength	Commercial assessment
Basic dexrazoxane composition	Low for a mature product	Likely subject to expired or well-established technology
Mannitol lyophilized formulation	Low	Conventional excipient strategy
Specific stability profile	Moderate	Depends on claim breadth and reproducibility
Reconstitution system	Moderate	Stronger if linked to measurable safety or workflow benefits
Method of use	Moderate to high	Depends on listed claims and label carve-out options
Manufacturing impurity control	Moderate	Can delay approval if difficult to reproduce
Device-enabled presentation	Moderate to high	May support differentiated hospital contracting

Manufacturing know-how can matter more than patents. Dexrazoxane injection requires a validated sterile process, consistent lyophilization, reliable reconstitution, and tight control of visible and subvisible particles. These requirements create barriers for small manufacturers even when legal exclusivity is limited.

What generic launch risks exist for dexrazoxane injection?

Generic launch risk is concentrated in five areas:

1. Small market size. The labeled population is narrow, reducing the return on development and launch investment.
2. Sterile manufacturing complexity. Injectable quality failures can cause recalls, shortages, and regulatory action.
3. Hospital purchasing concentration. Group purchasing organizations and oncology distributors can compress margins.
4. Supply reliability. A single manufacturing interruption can remove a competitor from the market.
5. Indication and labeling constraints. Method-of-use carve-outs may limit commercial positioning.

A successful entrant would need a reliable API source, redundant fill-finish capacity, competitive vial economics, and a hospital-focused distribution plan.

How does Zinecard compare with Totect?

Attribute	Zinecard	Totect
Active ingredient	Dexrazoxane hydrochloride	Dexrazoxane hydrochloride
Primary use	Doxorubicin cardioprotection	Anthracycline extravasation
Dosage form	Lyophilized injection	Product-specific formulation and preparation
Commercial buyer	Oncology hospitals and infusion centers	Hospitals, emergency oncology services, infusion centers
Differentiation	Cardioprotection protocol and dose efficiency	Extravasation response, availability, and emergency readiness
Substitution analysis	Must follow approved product and Orange Book rules	Must be evaluated separately by product and indication

The products share an active ingredient but should not be treated as interchangeable commercial assets. Separate labeling, dosing, evidence, and purchasing behavior affect market access.

What revenue exposure does Zinecard have?

Public company filings generally do not report Zinecard revenue as a separate line item. The product’s economic exposure is best estimated through unit demand, average selling price, treatment volumes, and competitor supply.

Revenue is likely most sensitive to:

• Anthracycline treatment volume.
• Adoption of cardioprotective protocols.
• Generic price erosion.
• Hospital formulary inclusion.
• Product shortages.
• Use outside the narrow U.S. label.
• Expansion into pediatric or other specialty populations.

The small market size can support premium pricing for a dependable branded or authorized-generic product, particularly when shortages make availability more valuable than nominal unit price.

Key Takeaways

• Zinecard is a dexrazoxane hydrochloride lyophilized injection with mannitol as the principal listed inactive ingredient.
• The formulation is simple and offers limited scope for broad excipient-based exclusivity.
• The primary commercial barriers are sterile manufacturing, supply reliability, hospital contracting, and reconstitution performance.
• The strongest product opportunities are ready-to-use delivery, reduced vial waste, improved stability, and pharmacy workflow systems.
• Method-of-use patents and indication-specific labeling may remain relevant even when basic formulation protection is weak.
• Zinecard and Totect share dexrazoxane hydrochloride but address different clinical uses and should be analyzed separately.
• Generic entry risk is real, but the small market and sterile injectable economics may limit the number of sustained competitors.
• Current Orange Book entries, NDA 020212 records, and FDA-approved labeling control the final assessment of patent and substitution risk.

FAQs

Can mannitol be replaced in a generic Zinecard formulation?

Yes, a generic applicant may develop a different excipient composition if it satisfies pharmaceutical equivalence or applicable product-specific requirements. The replacement must support stability, sterility, reconstitution, and comparable clinical performance.

Is a liquid dexrazoxane formulation commercially attractive?

Potentially. A liquid product could reduce pharmacy preparation steps, but the sponsor would need to overcome degradation, container-closure, stability, and cold-chain or shelf-life constraints.

Does Zinecard have biosimilar competition?

No. Dexrazoxane is a small-molecule drug, so competition proceeds through generic drug pathways rather than biosimilar pathways.

Can a manufacturer patent a dexrazoxane vial configuration?

Yes. A vial configuration may be patentable if it includes a novel and non-obvious technical arrangement that produces a measurable benefit. A simple change in vial fill quantity generally provides limited patent strength by itself.

What is the most defensible commercial differentiation for a dexrazoxane generic?

Reliable supply combined with lower dose waste, simplified reconstitution, validated stability, and strong hospital distribution is likely more defensible than a conventional mannitol-based composition alone.

References

1. Pfizer Inc. (n.d.). Zinecard (dexrazoxane hydrochloride) for injection: U.S. prescribing information. U.S. Food and Drug Administration.
2. U.S. Food and Drug Administration. (2024). Sterile drug products produced by aseptic processing: Current good manufacturing practice.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters for sterile products, particulate matter, and injectable preparations.